Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCF Induction Followed by Cetuximab-Radiotherapy in Head and Neck Cancer
NCT00502463Phase 2Completed
- Sponsor
- Austrian South Oncology Group
- Start
- Oct 2007
- Primary completion
- Jan 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in head and neck cancer (HNC), sponsored by Austrian South Oncology Group. Started Oct 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00502463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502463.